IL132560A0 - A method for making multispecific antibodies having heteromultimeric and common components - Google Patents

A method for making multispecific antibodies having heteromultimeric and common components

Info

Publication number
IL132560A0
IL132560A0 IL13256098A IL13256098A IL132560A0 IL 132560 A0 IL132560 A0 IL 132560A0 IL 13256098 A IL13256098 A IL 13256098A IL 13256098 A IL13256098 A IL 13256098A IL 132560 A0 IL132560 A0 IL 132560A0
Authority
IL
Israel
Prior art keywords
polypeptide
interface
formation
antibody
heteromultimers
Prior art date
Application number
IL13256098A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL132560A0 publication Critical patent/IL132560A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/972Modified antibody, e.g. hybrid, bifunctional

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
IL13256098A 1997-05-02 1998-04-30 A method for making multispecific antibodies having heteromultimeric and common components IL132560A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85005897A 1997-05-02 1997-05-02
US5066197P 1997-06-24 1997-06-24
PCT/US1998/008762 WO1998050431A2 (en) 1997-05-02 1998-04-30 A method for making multispecific antibodies having heteromultimeric and common components

Publications (1)

Publication Number Publication Date
IL132560A0 true IL132560A0 (en) 2001-03-19

Family

ID=26728503

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13256098A IL132560A0 (en) 1997-05-02 1998-04-30 A method for making multispecific antibodies having heteromultimeric and common components

Country Status (11)

Country Link
US (2) US8642745B2 (xx)
EP (1) EP0979281B1 (xx)
JP (2) JP4213224B2 (xx)
AT (1) ATE299938T1 (xx)
AU (1) AU751659B2 (xx)
CA (1) CA2288600C (xx)
DE (1) DE69830901T2 (xx)
DK (1) DK0979281T3 (xx)
ES (1) ES2246069T3 (xx)
IL (1) IL132560A0 (xx)
WO (1) WO1998050431A2 (xx)

Families Citing this family (639)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
SI1157041T1 (sl) * 1999-03-01 2005-12-31 Genentech Inc Protitelesa za terapijo in diagnozo raka
CA2361877A1 (en) * 1999-03-01 2000-09-08 Genentech, Inc. Antibodies for cancer therapy and diagnosis
EP1074563A1 (en) * 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
SE0000597D0 (sv) * 2000-02-24 2000-02-24 Active Biotech Ab Novel antibody
AU5720601A (en) * 2000-04-26 2001-11-07 Elusys Therapeutics Inc Bispecific molecules and uses thereof
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20040136949A1 (en) 2001-04-24 2004-07-15 Matthias Grell Combination therapy using anti-angiogenic agents and tnf alpha
AU2003227504A1 (en) 2002-04-15 2003-10-27 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
JP4518941B2 (ja) 2002-04-26 2010-08-04 中外製薬株式会社 アゴニスト抗体のスクリーニング方法
CA2965865C (en) * 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
AU2013200009B2 (en) * 2002-07-18 2015-05-07 Merus N.V. Recombinant production of mixtures of antibodies
WO2004065611A1 (ja) * 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗体の軽鎖スクリーニング方法
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2003280713A1 (en) * 2003-11-04 2005-05-19 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
ATE516048T1 (de) * 2004-06-01 2011-07-15 Merck Sharp & Dohme Mit hiv gp41 in wechselwirkung stehende menschliche antikörper
EP1870458B1 (en) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
ES2494921T3 (es) * 2005-04-08 2014-09-16 Chugai Seiyaku Kabushiki Kaisha Anticuerpo que sustituye la función del factor VIII de coagulación sanguínea
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
US20110040073A1 (en) * 2006-04-07 2011-02-17 Novo Nordisk Healthcare A/G Covalent Factor VII-Tissue Factor Complex
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
EP2035456A1 (en) * 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
JP5368301B2 (ja) 2006-06-22 2013-12-18 ノボ・ノルデイスク・エー/エス 可溶性ヘテロ二量体レセプター及びその使用
JP5087625B2 (ja) 2006-09-01 2012-12-05 セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド 非ヒトトランスジェニック動物におけるヒトまたはヒト化免疫グロブリンの発現強化
BRPI0717431A2 (pt) 2006-09-29 2013-11-12 Oncomed Pharm Inc Composições e métodos de diagnóstico e tratamento do câncer
MX2009007597A (es) 2007-01-18 2009-07-22 Merck Patent Gmbh Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
ES2499391T5 (es) 2007-10-15 2021-12-22 Chugai Pharmaceutical Co Ltd Método para la producción de anticuerpos
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
ES2689274T3 (es) 2008-01-03 2018-11-13 The Scripps Research Institute Dirección de anticuerpos mediante un dominio de reconocimiento modular
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
ES2906344T3 (es) * 2008-06-27 2022-04-18 Merus Nv Animal murino transgénico productor de anticuerpos
JP5560270B2 (ja) 2008-07-08 2014-07-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Notch結合剤およびアンタゴニストならびにその使用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2010019702A2 (en) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Ddr1-binding agents and methods of use thereof
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010068722A1 (en) 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
RU2598248C2 (ru) 2009-04-02 2016-09-20 Роше Гликарт Аг Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
BRPI1011206A2 (pt) 2009-05-25 2016-03-15 Merck Patent Gmbh administração contínua de ligantes de integrina para tratar câncer
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
TWI505836B (zh) 2009-12-11 2015-11-01 Genentech Inc 抗-vegf-c抗體及其使用方法
HUE027713T2 (en) 2009-12-23 2016-10-28 Hoffmann La Roche Anti-BV8 antibodies and their use
CN102770537A (zh) 2009-12-25 2012-11-07 中外制药株式会社 用于纯化多肽多聚体的多肽的修饰方法
EP2530109A4 (en) 2010-01-29 2013-08-28 Toray Industries RESIN SHEET BASED ON POLYLACTIC ACID
RU2724663C2 (ru) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CA2796633C (en) * 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP2593122A1 (en) 2010-07-16 2013-05-22 Merck Patent GmbH Peptide for use in the treatment of breast cancer and/or bone metastases
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
KR20130100125A (ko) 2010-08-13 2013-09-09 제넨테크, 인크. 질환의 치료를 위한, IL-1β 및 IL-18에 대한 항체
MX338953B (es) 2010-08-16 2016-05-06 Novimmune Sa Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR101398363B1 (ko) * 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
EP4303236A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
KR101638224B1 (ko) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 항원 결합 단백질
JP6101638B2 (ja) * 2011-03-03 2017-03-22 ザイムワークス,インコーポレイテッド 多価ヘテロマルチマー足場設計及び構築物
US20140056897A1 (en) 2011-03-10 2014-02-27 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
AU2012227883A1 (en) 2011-03-17 2013-10-24 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
CN107840894A (zh) 2011-03-25 2018-03-27 格兰马克药品股份有限公司 异二聚体免疫球蛋白
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
GB201109965D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating estrogen receptor alpher(ER) positive cancer
WO2012176779A1 (ja) 2011-06-20 2012-12-27 協和発酵キリン株式会社 抗erbB3抗体
BR112013032630B1 (pt) 2011-06-30 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Polipeptídeo heterodimerizado compreendendo região fc de igg
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013010840A2 (en) 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
JP2014533930A (ja) 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
HRP20240230T1 (hr) 2011-10-11 2024-04-26 F. Hoffmann - La Roche Ag Poboljšani sklop bispecifičnih protutijela
EP2771028A2 (en) 2011-10-24 2014-09-03 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
EP3674320A3 (en) 2011-10-27 2020-08-12 Genmab A/S Production of heterodimeric proteins
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
SI2794905T1 (sl) 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
JP2015503907A (ja) * 2011-12-22 2015-02-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 真核細胞のための全長抗体提示システムおよびその使用
KR20140127854A (ko) 2012-02-10 2014-11-04 제넨테크, 인크. 단일-쇄 항체 및 다른 이종다량체
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
PT2825037T (pt) 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
SG10201607727PA (en) 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
HUE053310T2 (hu) 2012-03-16 2021-06-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JP6007310B2 (ja) 2012-04-05 2016-10-12 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ヒトtweak及びヒトil17に対する二重特異性抗体並びにその使用
AU2013249985B2 (en) * 2012-04-20 2017-11-23 Merus N.V. Methods and means for the production of Ig-like molecules
MX2019001355A (es) * 2012-05-10 2023-01-17 Bioatla Llc Anticuerpos monoclonales multiespecíficos.
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたFc領域を含む抗原結合分子
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
EP3339328A1 (en) 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
MX353951B (es) 2012-07-04 2018-02-07 Hoffmann La Roche Anticuerpos de anti-teofilina y metodos de uso.
WO2014006124A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
WO2014012082A2 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
ES2692951T3 (es) * 2012-09-27 2018-12-05 Merus N.V. Anticuerpos IgG biespecíficos como acopladores de células T
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
US10344099B2 (en) 2012-11-05 2019-07-09 Zenyaku Kogyo Kabushikikaisha Antibody and antibody composition production method
SG11201502876RA (en) 2012-11-08 2015-06-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
WO2014108198A1 (en) 2013-01-10 2014-07-17 Genmab B.V. Human igg1 fc region variants and uses thereof
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JP6499087B2 (ja) 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー 二重特異性t細胞活性化抗原結合分子
ES2775207T3 (es) 2013-02-26 2020-07-24 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas específicas para CD3 y CEA
PL2968520T3 (pl) * 2013-03-14 2022-01-03 Macrogenics, Inc. Dwuspecyficzne cząsteczki, które są immunoreaktywne wobec immunologicznych komórek efektorowych wykazujących ekspresję receptora aktywującego
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
AU2014261631B2 (en) 2013-04-29 2019-02-14 F. Hoffmann-La Roche Ag FcRn-binding abolished anti-IGF-1R antibodies and their use in the treatment of vascular eye diseases
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
JP6618893B2 (ja) 2013-04-29 2019-12-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Fc受容体結合が変更された非対称抗体および使用方法
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CN113248615A (zh) 2013-07-05 2021-08-13 根马布股份公司 人源化或嵌合cd3抗体
WO2015017548A2 (en) * 2013-07-31 2015-02-05 Amgen Inc. Stabilization of fc-containing polypeptides
EP3050896B1 (en) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
MX2016003617A (es) 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 多重特異性ドメイン交換共通可変軽鎖抗体
JPWO2015068847A1 (ja) 2013-11-11 2017-03-09 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
DK3736292T3 (da) 2013-12-17 2024-07-22 Genentech Inc Anti-CD3-antistoffer og fremgangsmåder til anvendelse
CA2925677A1 (en) * 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
BR112016013562A2 (pt) 2013-12-20 2017-10-03 Hoffmann La Roche Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
CA2930154A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
CA2933384A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
EP3851452A1 (en) 2014-01-06 2021-07-21 F. Hoffmann-La Roche AG Monovalent blood brain barrier shuttle modules
CN105899534B (zh) 2014-01-15 2020-01-07 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
KR20160124165A (ko) 2014-02-21 2016-10-26 제넨테크, 인크. 항-il-13/il-17 이중특이적 항체 및 그의 용도
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
KR20240042540A (ko) 2014-02-28 2024-04-02 메뤼스 엔.페. ErbB-2와 ErbB-3에 결합하는 항체
JP6644717B2 (ja) 2014-03-14 2020-02-12 ジェネンテック, インコーポレイテッド 異種ポリペプチドを分泌させるための方法及び組成物
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
WO2015153765A1 (en) * 2014-04-01 2015-10-08 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP6666262B2 (ja) 2014-04-02 2020-03-13 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 多重特異性抗体の軽鎖誤対合を検出するための方法
CA2943943C (en) 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
CN106471117A (zh) 2014-05-06 2017-03-01 豪夫迈·罗氏有限公司 使用哺乳动物细胞产生异多聚体蛋白
DK3142750T3 (da) 2014-05-13 2020-09-14 Univ Pennsylvania Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
BR112016029935A2 (pt) 2014-06-26 2017-10-31 Hoffmann La Roche ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
CN107074948B (zh) 2014-07-11 2022-01-28 根马布股份公司 结合axl的抗体
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
AR101846A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados
PT3191135T (pt) 2014-09-12 2020-11-12 Genentech Inc Anticorpos anti-her2 e imunoconjugados
JP6730261B2 (ja) 2014-09-17 2020-07-29 ジェネンテック, インコーポレイテッド 抗her2抗体を含む免疫複合体
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定fviii的反應性之方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US11952421B2 (en) 2014-10-09 2024-04-09 Bristol-Myers Squibb Company Bispecific antibodies against CD3EPSILON and ROR1
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
ES2749383T3 (es) 2014-11-06 2020-03-20 Hoffmann La Roche Variantes de la región Fc con unión al FcRn modificada y procedimientos de uso
KR20170076697A (ko) 2014-11-06 2017-07-04 에프. 호프만-라 로슈 아게 개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체
JP6594438B2 (ja) 2014-11-07 2019-10-23 セセン バイオ, インコーポレイテッド 改善されたil−6抗体
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
DK3789402T3 (da) 2014-11-20 2022-09-19 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
RS60615B1 (sr) 2014-11-20 2020-08-31 Hoffmann La Roche Zajednički laki lanci i postupci upotrebe
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
MX2017007491A (es) 2014-12-10 2018-05-04 Genentech Inc Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
EP3233907B1 (en) 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
EP3302552A1 (en) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
AR105026A1 (es) 2015-06-16 2017-08-30 Genentech Inc ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
EP3313890A1 (en) * 2015-06-24 2018-05-02 H. Hoffnabb-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
US9862763B2 (en) 2015-06-24 2018-01-09 Hoffmann-La Roche Inc. Humanized anti-tau(pS422) antibodies and methods of use
PT3319993T (pt) 2015-07-10 2020-04-22 Genmab As Conjugados de anticorpo-fármaco específicos de axl para tratamento de cancro
CA2991880A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
CN108368172B (zh) 2015-07-15 2022-06-14 根马布股份公司 人源化或嵌合cd3抗体
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356410B1 (en) 2015-10-02 2021-10-20 F. Hoffmann-La Roche AG Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
JP6734919B2 (ja) 2015-10-02 2020-08-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 同時結合を測定するための細胞ベースのfretアッセイ法
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
EP3913000A1 (en) 2015-10-02 2021-11-24 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
UA124925C2 (en) 2015-10-02 2021-12-15 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
AR106199A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas activadoras de células t
WO2017055395A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
EP3150637A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Multispecific antibodies
CN108026179A (zh) 2015-10-02 2018-05-11 豪夫迈·罗氏有限公司 结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
RU2731202C2 (ru) 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
SI3365373T1 (sl) 2015-10-23 2021-08-31 Merus N.V. Vezne molekule, ki zaviranjo rast raka
SG10202006332PA (en) * 2015-10-29 2020-08-28 Hoffmann La Roche Transgenic rabbit with common light chain
IL295756A (en) 2015-10-29 2022-10-01 Hoffmann La Roche Antibodies against fc-variable region and methods of use
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Cd3及びpsmaに結合するヘテロ二量体抗体
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
WO2017115773A1 (ja) 2015-12-28 2017-07-06 中外製薬株式会社 Fc領域含有ポリペプチドの精製を効率化するための方法
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
JP7046814B2 (ja) 2015-12-30 2022-04-04 ジェネンテック, インコーポレイテッド タンパク質製剤のためのトリプトファン誘導体の使用
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
SI3433280T1 (sl) 2016-03-22 2023-07-31 F. Hoffmann-La Roche Ag S proteazo aktivirane bispecifične molekule celic T
NZ746934A (en) 2016-04-15 2023-11-24 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
SG11201809620UA (en) 2016-05-02 2018-11-29 Hoffmann La Roche The contorsbody - a single chain target binder
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
CN110603266A (zh) 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CN109563124A (zh) 2016-06-17 2019-04-02 豪夫迈·罗氏有限公司 多特异性抗体的纯化
EP3475304B1 (en) 2016-06-28 2022-03-23 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
EP4410378A3 (en) 2016-07-01 2024-10-09 Resolve Therapeutics, LLC Optimized binuclease fusions and methods
EP3478717B1 (en) 2016-07-04 2022-01-05 F. Hoffmann-La Roche AG Novel antibody format
BR112019000512A2 (pt) 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
CR20220408A (es) 2016-09-14 2022-10-20 Teneobio Inc ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198)
JP6785372B2 (ja) 2016-09-30 2020-11-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 多重特異性分子の機能分析のためのsprに基づく二重結合アッセイ
WO2018060301A1 (en) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Bispecific antibodies against cd3
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
PE20191034A1 (es) 2016-10-14 2019-08-05 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1
BR112019008702A2 (pt) 2016-11-01 2019-07-16 Genmab B.V. polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
MX2019005438A (es) 2016-11-15 2019-08-16 Genentech Inc Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AU2017367695A1 (en) 2016-12-02 2019-06-13 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Antibodies against BCMA containing only heavy chains and their uses
TWI837084B (zh) 2017-02-01 2024-04-01 丹麥商諾佛 儂迪克股份有限公司 促凝血抗體
SG11201906961UA (en) 2017-02-10 2019-08-27 Genmab Bv Polypeptide variants and uses thereof
CA3055127A1 (en) 2017-03-09 2018-09-13 Genmab A/S Antibodies against pd-l1
NZ756132A (en) 2017-03-10 2022-02-25 Hoffmann La Roche Method for producing multispecific antibodies
RS64870B1 (sr) 2017-03-16 2023-12-29 Alpine Immune Sciences Inc Imunomodulatorni proteini varijante pd-l1 i njihove upotrebe
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
SG11201907769XA (en) 2017-03-16 2019-09-27 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
EP3604340A4 (en) 2017-03-24 2021-01-06 Zenyaku Kogyo Co., Ltd ANTI-IGM / B-CELL SURFACE ANTIGEN-BISPECIFIC ANTIBODY
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
NZ757603A (en) 2017-03-31 2024-05-31 Genmab Holding B V Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
PE20191494A1 (es) 2017-04-03 2019-10-21 Hoffmann La Roche Inmunoconjugados de un anticuerpo anti-pd-1 con un il-2 mutante o con il-15
JP7247101B2 (ja) 2017-04-03 2023-03-28 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Steap-1に結合する抗体
CN110382525B (zh) 2017-04-03 2023-10-20 豪夫迈·罗氏有限公司 免疫缀合物
CA3053360A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Anti-lag3 antibodies
TWI690538B (zh) 2017-04-05 2020-04-11 瑞士商赫孚孟拉羅股份公司 特異性結合至pd1至lag3的雙特異性抗體
AU2018250641A1 (en) 2017-04-11 2019-10-31 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
JP2020522254A (ja) * 2017-05-31 2020-07-30 エルスター セラピューティクス, インコーポレイテッド 骨髄増殖性白血病(mpl)タンパク質に結合する多特異性分子およびその使用
CN111328335A (zh) 2017-06-07 2020-06-23 根马布私人有限公司 基于突变igg六聚体的治疗性抗体
IL312322A (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
EP3649154A1 (en) 2017-07-06 2020-05-13 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
US20190016804A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
KR20200042485A (ko) 2017-08-09 2020-04-23 메뤼스 엔.페. EGFR 및 cMET에 결합하는 항체
JP7374091B2 (ja) 2017-08-22 2023-11-06 サナバイオ, エルエルシー 可溶性インターフェロン受容体およびその使用
EP3457139A1 (en) 2017-09-19 2019-03-20 Promise Advanced Proteomics Antibody-like peptides for quantifying therapeutic antibodies
JP6496095B1 (ja) 2017-09-29 2019-04-03 中外製薬株式会社 血液凝固第viii因子(fviii)補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
EP4219540A3 (en) 2017-10-10 2023-12-06 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
TW201925223A (zh) 2017-10-18 2019-07-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
EP3697441B1 (en) 2017-10-20 2023-06-07 F. Hoffmann-La Roche AG Method for generating multispecific antibodies from monospecific antibodies
BR112020007736A2 (pt) 2017-10-30 2020-10-20 F. Hoffmann-La Roche Ag composição e método de tratamento
AU2018358904A1 (en) 2017-11-01 2020-04-16 F. Hoffmann-La Roche Ag TriFab-contorsbody
WO2019086394A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag The compbody - a multivalent target binder
MA50505A (fr) 2017-11-01 2020-09-09 Hoffmann La Roche Anticorps 2 + 1 bispécifiques (contorsbodies)
WO2019086499A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Novel tnf family ligand trimer-containing antigen binding molecules
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
EP3706793A1 (en) 2017-11-08 2020-09-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
WO2019093342A1 (ja) 2017-11-08 2019-05-16 協和発酵キリン株式会社 CD40とEpCAMに結合するバイスペシフィック抗体
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019126401A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたil−2 fc融合タンパク質
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
EP3728323A4 (en) 2017-12-19 2022-01-26 Surrozen Operating, Inc. ANTI-FZD ANTIBODIES AND METHODS OF USE
MX2020006119A (es) 2017-12-21 2020-08-24 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1.
WO2019122054A1 (en) 2017-12-22 2019-06-27 F. Hoffmann-La Roche Ag Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
WO2019133761A1 (en) 2017-12-27 2019-07-04 Teneobio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
EP3731865A1 (en) 2017-12-29 2020-11-04 F. Hoffmann-La Roche AG Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
WO2019145455A1 (en) 2018-01-24 2019-08-01 Genmab B.V. Polypeptide variants and uses thereof
CN111655730A (zh) 2018-01-31 2020-09-11 豪夫迈·罗氏有限公司 包含与lag3结合的抗原结合位点的双特异性抗体
CN111630063A (zh) 2018-01-31 2020-09-04 豪夫迈·罗氏有限公司 稳定化的免疫球蛋白结构域
SG11202006712XA (en) 2018-02-06 2020-08-28 Hoffmann La Roche Treatment of ophthalmologic diseases
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
JP7515412B2 (ja) 2018-03-09 2024-07-12 アスクジーン・ファーマ・インコーポレイテッド 新規のサイトカインプロドラッグ
EP3765493A2 (en) 2018-03-12 2021-01-20 Genmab A/S Antibodies
JP2021519073A (ja) 2018-03-29 2021-08-10 ジェネンテック, インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
AR115320A1 (es) 2018-03-30 2020-12-23 Merus Nv Anticuerpo multivalente
TW202003567A (zh) 2018-03-30 2020-01-16 大陸商南京傳奇生物科技有限公司 針對lag-3之單一結構域抗體及其用途
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US20190330366A1 (en) 2018-04-11 2019-10-31 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
GB201808927D0 (en) 2018-05-31 2018-07-18 Institute Of Cancer Res Royal Cancer Hospital Materials and methods for monitoring the development of resistance of cancers to treatment
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2019244973A1 (ja) 2018-06-20 2019-12-26 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
TW202019518A (zh) 2018-07-13 2020-06-01 丹麥商珍美寶股份有限公司 Cd38抗體之變體及其用途
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
JP2021530243A (ja) 2018-07-25 2021-11-11 アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. 新規il−21プロドラッグおよびそれを使用する方法
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
EP3830135A1 (en) * 2018-08-01 2021-06-09 Novo Nordisk A/S Improved procoagulant antibodies
CA3106537A1 (en) 2018-08-08 2020-02-13 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
BR112021004436A2 (pt) * 2018-09-10 2021-05-25 Genentech, Inc. sistema e método para separar proteínas de múltiplas subunidades em uma amostra, método para isolar uma proteína alvo em uma mistura de amostra e ligante de eletroforese capilar de afinidade
AU2019345151A1 (en) 2018-09-19 2021-04-29 Alpine Immune Sciences, Inc. Methods and uses of variant CD80 fusion proteins and related constructs
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
US20240252635A1 (en) 2018-10-04 2024-08-01 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CA3115082A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
US20210380679A1 (en) 2018-10-11 2021-12-09 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
CA3114693A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
AU2019370601B2 (en) 2018-10-29 2024-05-23 F. Hoffmann-La Roche Ag Antibody formulation
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
WO2020094744A1 (en) 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
US20220041719A1 (en) 2018-12-05 2022-02-10 Morphosys Ag Multispecific antigen-binding molecules
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
SG10202105788SA (en) 2018-12-21 2021-06-29 Hoffmann La Roche Antibodies binding to cd3
US20220064327A1 (en) 2018-12-21 2022-03-03 Kymab Limited Fixaxfx bispecific antibody with common light chain
CN113412123A (zh) 2018-12-28 2021-09-17 豪夫迈·罗氏有限公司 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白
CA3125316A1 (en) 2018-12-28 2020-07-02 Kyowa Kirin Co., Ltd. Bispecific antibody binding to tfr
CN113439089A (zh) * 2018-12-31 2021-09-24 美勒斯公司 截短的多价多元体
AU2020204992A1 (en) 2019-01-04 2021-07-15 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JP2022523946A (ja) 2019-03-01 2022-04-27 ゼンコア インコーポレイテッド Enpp3およびcd3に結合するヘテロ二量体抗体
JP7249432B2 (ja) 2019-03-29 2023-03-30 エフ. ホフマン-ラ ロシュ アーゲー 多価分子の機能分析のための、sprをベースとする結合アッセイ
CN113677701A (zh) 2019-03-29 2021-11-19 豪夫迈·罗氏有限公司 产生亲合结合多特异性抗体的方法
EP3956359A1 (en) 2019-04-17 2022-02-23 Novo Nordisk A/S Bispecific antibodies
CN114302736A (zh) 2019-04-17 2022-04-08 高山免疫科学股份有限公司 变体icos配体(icosl)融合蛋白的方法和用途
CA3133898A1 (en) 2019-04-25 2020-10-29 Ulrich Brinkmann Activatable therapeutic multispecific polypeptides with extended half-life
MX2021012872A (es) 2019-04-25 2021-11-17 Hoffmann La Roche Polipeptidos multiespecificos terapeuticos activados mediante intercambio de cadenas polipeptidicas.
CA3132275A1 (en) 2019-04-25 2020-10-29 Ulrich Brinkmann Generation of antibody-derived polypeptides by polypeptide chain exchange
JP2022531894A (ja) 2019-05-09 2022-07-12 ゲンマブ ビー.ブイ. がんの処置において使用するための抗dr5抗体の組み合わせの投与レジメン
EP3969907A1 (en) 2019-05-13 2022-03-23 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay
KR20220008820A (ko) 2019-05-15 2022-01-21 쿄와 기린 가부시키가이샤 Cd40과 fap에 결합하는 이중 특이적 항체
EP3971293A4 (en) 2019-05-15 2023-02-08 Kyowa Kirin Co., Ltd. BISPECIFIC ANTIBODIES CAPABLE OF BINDING TO CD40 AND GPC3
MX2021014433A (es) 2019-06-05 2022-03-11 Chugai Pharmaceutical Co Ltd Molecula de union a sitio de escision de anticuerpo.
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
CA3140816A1 (en) 2019-06-14 2020-12-17 Nathan Trinklein Multispecific heavy chain antibodies binding to cd22 and cd3
WO2020254357A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Method for the generation of a protein expressing cell by targeted integration using cre mrna
JP7450647B2 (ja) 2019-06-26 2024-03-15 エフ. ホフマン-ラ ロシュ アーゲー Sirt-1遺伝子ノックアウトを有する哺乳類細胞株
WO2021001289A1 (en) 2019-07-02 2021-01-07 F. Hoffmann-La Roche Ag Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
MX2022000111A (es) 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CN115175932A (zh) 2019-07-16 2022-10-11 赛诺菲 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
EP4004045A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Antibodies binding to gprc5d
MX2022001156A (es) 2019-07-31 2022-02-22 Hoffmann La Roche Anticuerpos que se fijan a gprc5d.
JP2022544771A (ja) 2019-08-12 2022-10-21 アスクジーン・ファーマ・インコーポレイテッド 優先的にil-2rアルファに結合するil-2融合タンパク質
WO2021035188A1 (en) 2019-08-21 2021-02-25 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
AU2020349509A1 (en) 2019-09-18 2022-03-31 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
EP4034570A4 (en) * 2019-09-27 2023-10-25 Agenus Inc. HETERODIMERIC PROTEINS
EP4034551A1 (en) 2019-09-28 2022-08-03 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
CA3156080A1 (en) 2019-09-29 2021-04-01 Jacobio Pharmaceuticals Co., Ltd. LIF SPECIFIC BINDING MOLECULE AND ITS USE
EP4055046A1 (en) 2019-11-06 2022-09-14 Genmab B.V. Antibody variant combinations and uses thereof
EP4057980A1 (en) 2019-11-15 2022-09-21 F. Hoffmann-La Roche AG Prevention of visible particle formation in aqueous protein solutions
TW202128767A (zh) 2019-12-13 2021-08-01 美商建南德克公司 抗ly6g6d抗體及其使用方法
CA3164818A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
PE20221282A1 (es) 2019-12-18 2022-09-05 Hoffmann La Roche Anticuerpos que se unen a hla-a2/mage-a4
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
PE20221186A1 (es) 2019-12-23 2022-08-05 Genentech Inc Anticuerpos especificos de apolipoproteina l1 y metodos de uso
IL294226A (en) 2019-12-27 2022-08-01 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibodies and their use
WO2021136772A1 (en) 2020-01-02 2021-07-08 F. Hoffmann-La Roche Ag Method for determining the amount of a therapeutic antibody in the brain
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
EP4090666A1 (en) 2020-01-15 2022-11-23 F. Hoffmann-La Roche AG Methods to decrease impurities from recombinant protein manufacturing processes
WO2021144457A1 (en) 2020-01-16 2021-07-22 Genmab A/S Formulations of cd38 antibodies and uses thereof
MX2022009306A (es) 2020-01-29 2022-09-26 Inhibrx Inc Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
WO2021173844A1 (en) 2020-02-26 2021-09-02 Biograph 55, Inc. C19 c38 bispecific antibodies
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Antibodies against interleukin-33 and uses thereof
AR121599A1 (es) 2020-03-18 2022-06-22 Genmab As Anticuerpos
TW202202620A (zh) 2020-03-26 2022-01-16 美商建南德克公司 經修飾之哺乳動物細胞
BR112022016695A2 (pt) 2020-03-30 2022-11-16 Univ Mie Anticorpo biespecífico ou fragmento de ligação do mesmo, polinucleotídeo, vetor, composição farmacêutica, molécula que se liga especificamente ao hla/ny-eso humano, seus usos, e métodos de produção de um anticorpo ou de uma molécula
KR20220161375A (ko) 2020-03-31 2022-12-06 추가이 세이야쿠 가부시키가이샤 다중 특이성 항원 결합 분자를 제조하기 위한 방법
CR20220512A (es) 2020-04-15 2022-11-07 Hoffmann La Roche Inmunoconjugados
CR20220531A (es) 2020-04-24 2022-11-28 Hoffmann La Roche Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
JP2023526774A (ja) 2020-04-29 2023-06-23 テネオバイオ, インコーポレイテッド 重鎖定常領域が修飾された多重特異性重鎖抗体
KR20230007384A (ko) 2020-04-30 2023-01-12 브리스톨-마이어스 스큅 컴퍼니 치료 방법
BR112022022730A2 (pt) 2020-05-08 2023-02-14 Genmab As Método para tratar um linfoma não hodgkin de células b em um indivíduo humano
MX2022013998A (es) 2020-05-08 2023-02-16 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas.
AU2021272340A1 (en) 2020-05-11 2022-12-08 F. Hoffmann-La Roche Ag Combination therapy with modified pbmcs and an immunoconjugate
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CN115605184A (zh) 2020-05-15 2023-01-13 豪夫迈·罗氏有限公司(Ch) 防止胃肠外蛋白质溶液中的可见颗粒形成
EP4153130A1 (en) 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions
JPWO2021241616A1 (xx) 2020-05-27 2021-12-02
MX2022015206A (es) 2020-06-08 2023-01-05 Hoffmann La Roche Anticuerpos anti-hbv y metodos de uso.
AU2021291407A1 (en) 2020-06-19 2022-09-29 F. Hoffmann-La Roche Ag Antibodies binding to CD3
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
CA3153085A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cd19
PE20230616A1 (es) 2020-06-19 2023-04-14 Hoffmann La Roche Anticuerpos que se unen a cd3 y folr1
EP4168445A1 (en) 2020-06-19 2023-04-26 F. Hoffmann-La Roche AG Immune activating fc domain binding molecules
MX2022016453A (es) 2020-06-24 2023-02-01 Genentech Inc Lineas celulares resistentes a la apoptosis.
EP4171614A1 (en) 2020-06-29 2023-05-03 Resolve Therapeutics, LLC Treatment of sjogren's syndrome with nuclease fusion proteins
CN116133689A (zh) 2020-07-07 2023-05-16 豪夫迈·罗氏有限公司 作为治疗性蛋白质制剂的稳定剂的替代表面活性剂
BR112023000204A2 (pt) 2020-07-10 2023-01-31 Hoffmann La Roche Conjunto de anticorpos, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira, métodos de pré-direcionamento de radioimunoterapia e direcionamento de um radioisótopo, ligante peptídico, proteína de múltiplos domínios e usos
JP2023534458A (ja) 2020-07-17 2023-08-09 ジェネンテック, インコーポレイテッド 抗Notch2抗体及び使用方法
MX2023000888A (es) 2020-07-21 2023-02-22 Genentech Inc Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos.
JP2023534726A (ja) 2020-07-23 2023-08-10 ジェンマブ ビー.ブイ. 多発性骨髄腫の治療に使用するための抗dr5抗体と免疫調節イミド薬との併用
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
JPWO2022025220A1 (xx) 2020-07-31 2022-02-03
TW202212354A (zh) * 2020-08-03 2022-04-01 美商健生生物科技公司 用於病毒治療劑中之多向生物運輸的材料及方法
US20230287088A1 (en) 2020-08-06 2023-09-14 BioNTech SE Binding agents for coronavirus s protein
JP2023538891A (ja) 2020-08-19 2023-09-12 ゼンコア インコーポレイテッド 抗cd28組成物
EP4204558A2 (en) 2020-08-28 2023-07-05 Genentech, Inc. Crispr/cas9 multiplex knockout of host cell proteins
JPWO2022044248A1 (xx) 2020-08-28 2022-03-03
EP4210745A1 (en) 2020-09-10 2023-07-19 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
MX2023002540A (es) 2020-09-10 2023-03-14 Genmab As Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma folicular.
AU2021339006A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
AU2021341509A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
IL301085A (en) 2020-09-10 2023-05-01 Genmab As A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
KR20230073196A (ko) 2020-09-21 2023-05-25 제넨테크, 인크. 다중특이성 항체의 정제
AU2021347580A1 (en) 2020-09-24 2023-04-06 F. Hoffmann-La Roche Ag Mammalian cell lines with gene knockout
US20230365714A1 (en) 2020-10-02 2023-11-16 Genmab A/S Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
KR20230082632A (ko) 2020-10-05 2023-06-08 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
JP2023548249A (ja) 2020-11-10 2023-11-15 上海齊魯制藥研究中心有限公司 クローディン18a2及びcd3に対する二重特異性抗体及びその使用
AR124063A1 (es) 2020-11-16 2023-02-08 Astellas Pharma Inc Anticuerpo biespecífico anti-tspan8 / anti-cd3 y anticuerpo anti-tspan8
MX2023005581A (es) 2020-11-16 2023-05-29 Hoffmann La Roche Glucoformas de fab ricas en manosa.
JP2023551983A (ja) 2020-12-07 2023-12-13 ユーシービー バイオファルマ エスアールエル インターロイキン-22に対する抗体
IL303295A (en) 2020-12-07 2023-07-01 UCB Biopharma SRL Multispecific antibodies and antibody combinations
AU2021399841A1 (en) 2020-12-17 2023-07-06 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
WO2022129313A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag Precursor proteins and kit for targeted therapy
WO2022136140A1 (en) 2020-12-22 2022-06-30 F. Hoffmann-La Roche Ag Oligonucleotides targeting xbp1
KR20230117406A (ko) 2021-01-06 2023-08-08 에프. 호프만-라 로슈 아게 Pd1-lag3 이중특이성 항체와 cd20 t 세포 이중특이성항체를 이용한 조합 요법
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
WO2022152656A1 (en) 2021-01-12 2022-07-21 F. Hoffmann-La Roche Ag Split antibodies which bind to cancer cells and target radionuclides to said cells
MX2023008083A (es) 2021-01-13 2023-07-13 Hoffmann La Roche Tratamiento conjunto.
WO2022155541A1 (en) 2021-01-14 2022-07-21 AskGene Pharma, Inc. Interferon prodrugs and methods of making and using the same
WO2022165443A1 (en) 2021-02-01 2022-08-04 AskGene Pharma, Inc. Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
EP4288458A1 (en) 2021-02-03 2023-12-13 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
WO2022178103A1 (en) 2021-02-17 2022-08-25 AskGene Pharma, Inc. Il-2 receptor beta subunit mutants
JP2024512240A (ja) 2021-02-18 2024-03-19 エフ. ホフマン-ラ ロシュ アーゲー 複雑な多段階の抗体相互作用を解明するための方法
AU2022232375A1 (en) 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
EP4304732A1 (en) 2021-03-12 2024-01-17 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
CA3210971A1 (en) 2021-03-12 2022-09-15 Bart-Jan DE KREUK Non-activating antibody variants
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
JP2024514306A (ja) 2021-03-31 2024-04-01 エフ. ホフマン-ラ ロシュ アーゲー 混合モードクロマトグラフィーによる抗体の精製
CN116897159A (zh) 2021-03-31 2023-10-17 江苏恒瑞医药股份有限公司 截短的taci多肽及其融合蛋白和用途
WO2022214565A1 (en) 2021-04-09 2022-10-13 F. Hoffmann-La Roche Ag Process for selecting cell clones expressing a heterologous polypeptide
WO2022219080A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
EP4322937A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve the anti-tumoral activity of macrophages
CA3215965A1 (en) 2021-04-19 2022-10-27 Amy Shen Modified mammalian cells
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2024509664A (ja) 2021-04-30 2024-03-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗cd20/抗cd3二重特異性抗体による治療のための投薬
JP2024516305A (ja) 2021-05-03 2024-04-12 ユーシービー バイオファルマ エスアールエル 抗体
US20240279310A1 (en) 2021-05-07 2024-08-22 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
MX2023012351A (es) 2021-05-07 2023-10-31 Genmab As Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3).
KR20240006586A (ko) 2021-05-12 2024-01-15 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도
WO2022237882A1 (zh) 2021-05-14 2022-11-17 江苏恒瑞医药股份有限公司 一种抗原结合分子
JP2024521107A (ja) 2021-05-21 2024-05-28 ジェネンテック, インコーポレイテッド 目的の組換え産物を産生するための修飾細胞
JP2024527493A (ja) 2021-06-16 2024-07-25 アレクトル エルエルシー 一価の抗MerTK抗体及びその使用方法
EP4355786A1 (en) 2021-06-16 2024-04-24 Alector LLC Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
AU2022295067A1 (en) 2021-06-18 2023-12-21 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
BR112023027006A2 (pt) 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
EP4359083A1 (en) 2021-06-24 2024-05-01 Erasca, Inc. Antibodies against egfr and their uses
CA3221833A1 (en) 2021-06-25 2022-12-29 Chugai Seiyaku Kabushiki Kaisha Anti-ctla-4 antibody
CA3220353A1 (en) 2021-06-25 2022-12-29 Chugai Seiyaku Kabushiki Kaisha Use of anti-ctla-4 antibody
BR112023026966A2 (pt) 2021-07-02 2024-03-12 Hoffmann La Roche Métodos para tratar um indivíduo com melanoma, para alcançar uma resposta clínica, para tratar um indivíduo com linfoma não hodgkin, para tratar uma população de indivíduos com linfoma não hodgkin e para tratar um indivíduo com câncer colorretal metastático
JP2024529339A (ja) 2021-07-13 2024-08-06 ジェネンテック, インコーポレイテッド サイトカイン放出症候群を予測する多変量モデル
TW202317635A (zh) 2021-07-14 2023-05-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合hgfr和egfr的抗原結合分子及其醫藥用途
JP2024527606A (ja) 2021-07-14 2024-07-25 ジェネンテック, インコーポレイテッド 抗c-cモチーフケモカイン受容体8(ccr8)抗体及び使用方法
EP4373859A1 (en) 2021-07-22 2024-05-29 F. Hoffmann-La Roche AG Heterodimeric fc domain antibodies
CA3227537A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
EP4377351A1 (en) 2021-07-28 2024-06-05 F. Hoffmann-La Roche AG Methods and compositions for treating cancer
EP4380980A1 (en) 2021-08-03 2024-06-12 F. Hoffmann-La Roche AG Bispecific antibodies and methods of use
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
KR20240051280A (ko) 2021-09-06 2024-04-19 젠맵 에이/에스 Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도
TW202321312A (zh) 2021-09-08 2023-06-01 俄羅斯聯邦商拜奧卡德聯合股份公司 包含基於mhc或mhc樣蛋白的異源二聚體的二價雙特異性嵌合抗體
KR20240067092A (ko) 2021-09-23 2024-05-16 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-klb 항체 및 용도
JPWO2023053282A1 (xx) 2021-09-29 2023-04-06
WO2023051798A1 (zh) 2021-09-30 2023-04-06 江苏恒瑞医药股份有限公司 抗il23抗体融合蛋白及用途
US20230190807A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Tcr compounds, compositions, and methods of treating
AR127298A1 (es) 2021-10-08 2024-01-10 Genmab As Anticuerpos que se unen a cd30 y cd3
AR127269A1 (es) 2021-10-08 2024-01-03 Chugai Pharmaceutical Co Ltd Formulación de anticuerpo anti-hla-dq2.5
CN118139648A (zh) 2021-10-14 2024-06-04 豪夫迈·罗氏有限公司 用于治疗癌症的替代的PD1-IL7v免疫缀合物
CA3234731A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
WO2023094282A1 (en) 2021-11-25 2023-06-01 F. Hoffmann-La Roche Ag Quantification of low amounts of antibody sideproducts
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
AU2022413942A1 (en) 2021-12-13 2024-05-30 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-abcb1 antibodies
EP4416301A1 (en) 2021-12-21 2024-08-21 F. Hoffmann-La Roche AG Method for the determination of hydrolytic activity
TW202340251A (zh) 2022-01-19 2023-10-16 美商建南德克公司 抗notch2抗體及結合物及其使用方法
AU2023213099A1 (en) 2022-01-28 2024-07-18 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL314344A (en) 2022-01-28 2024-09-01 Genmab As Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
CN118574855A (zh) 2022-02-07 2024-08-30 江苏恒瑞医药股份有限公司 特异性结合psma和cd3的抗原结合分子及其医药用途
WO2023151661A1 (zh) 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 免疫缀合物及其用途
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
WO2023175064A1 (en) 2022-03-17 2023-09-21 Astrazeneca Ab Methods for purifying bispecific antibodies
WO2023180353A1 (en) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
AU2022450448A1 (en) 2022-04-01 2024-10-10 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202404637A (zh) 2022-04-13 2024-02-01 瑞士商赫孚孟拉羅股份公司 抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2023202967A1 (en) 2022-04-19 2023-10-26 F. Hoffmann-La Roche Ag Improved production cells
TWI833641B (zh) 2022-05-02 2024-02-21 丹麥商諾佛 儂迪克股份有限公司 適於高濃度組成物及皮下投藥之新穎抗angptl3抗體
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202413430A (zh) * 2022-05-12 2024-04-01 日商安斯泰來製藥股份有限公司 抗cd37和cd3的雙特異性抗體
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023218051A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023218431A1 (en) 2022-05-13 2023-11-16 BioNTech SE Rna compositions targeting hiv
WO2023232961A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Improved production cells
TW202417042A (zh) 2022-07-13 2024-05-01 美商建南德克公司 用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein
TW202421664A (zh) 2022-10-07 2024-06-01 美商建南德克公司 用抗c—c模體趨化因子受體8(ccr8)抗體治療癌症之方法
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Gprc5d tcb及cd38抗體之組合療法
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Gprc5d tcb及蛋白酶體抑制劑之組合療法
WO2024079015A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and imids
WO2024079069A1 (en) 2022-10-12 2024-04-18 F. Hoffmann-La Roche Ag Method for classifying cells
WO2024081918A1 (en) 2022-10-14 2024-04-18 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof
WO2024088921A1 (en) 2022-10-24 2024-05-02 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists
TW202426505A (zh) 2022-10-25 2024-07-01 美商建南德克公司 癌症之治療及診斷方法
WO2024094660A1 (en) 2022-10-31 2024-05-10 Genmab A/S Cd38 antibodies and uses thereof
WO2024094822A1 (en) 2022-11-02 2024-05-10 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
WO2024104988A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Recombinant binding proteins with activatable effector domain
WO2024104933A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Antigen binding molecules
WO2024110426A1 (en) 2022-11-23 2024-05-30 F. Hoffmann-La Roche Ag Method for increasing recombinant protein expression
WO2024110905A1 (en) 2022-11-24 2024-05-30 Beigene, Ltd. Anti-cea antibody drug conjugates and methods of use
WO2024119193A2 (en) 2022-12-02 2024-06-06 AskGene Pharma, Inc. Mutant il-2 polypeptides and il-2 prodrugs
WO2024129594A1 (en) 2022-12-12 2024-06-20 Genentech, Inc. Optimizing polypeptide sialic acid content
WO2024141955A1 (en) 2022-12-28 2024-07-04 BioNTech SE Rna compositions targeting hiv
WO2024155807A1 (en) 2023-01-18 2024-07-25 Genentech, Inc. Multispecific antibodies and uses thereof
WO2024153168A2 (en) 2023-01-19 2024-07-25 Beigene, Ltd. Anti-cmet antibodies and methods of use
WO2024153722A1 (en) 2023-01-20 2024-07-25 F. Hoffmann-La Roche Ag Immunoconjugates
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
WO2024163494A1 (en) 2023-01-31 2024-08-08 F. Hoffmann-La Roche Ag Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
WO2024183635A1 (en) 2023-03-03 2024-09-12 Beigene, Ltd. Muc1 and cd16a antibodies and methods of use
WO2024183637A1 (en) 2023-03-03 2024-09-12 Beigene Switzerland Gmbh Muc1 antibodies and methods of use
WO2024183636A1 (en) 2023-03-03 2024-09-12 Beigene Switzerland Gmbh Cd16a antibodies and methods of use
WO2024184287A1 (en) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
WO2024184810A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024184811A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cd3 multispecific antibodies and methods of use
WO2024184812A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 antibodies and methods of use
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
GB202303784D0 (en) 2023-03-15 2023-04-26 Institute Of Cancer Res Royal Cancer Hospital Cancer treatment
US20240327522A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024208776A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag Agonistic split antibodies
WO2024208777A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag All-in-one agonistic antibodies
WO2024208898A1 (en) 2023-04-05 2024-10-10 Genmab A/S Pharmaceutical compositions comprising antibodies binding to cd30 and cd3

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6121424A (en) * 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2097060A1 (en) * 1990-12-04 1992-06-05 Peter J. Curtis Bifunctional antibodies and method of preparing same
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JPH11508126A (ja) 1995-05-23 1999-07-21 モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー 多量体タンパク質
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
AU2002359815A1 (en) * 2001-12-19 2003-07-09 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
CA2965865C (en) * 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies

Also Published As

Publication number Publication date
JP4213224B2 (ja) 2009-01-21
JP4324231B2 (ja) 2009-09-02
ES2246069T3 (es) 2006-02-01
US9409989B2 (en) 2016-08-09
EP0979281B1 (en) 2005-07-20
US20070178552A1 (en) 2007-08-02
AU751659B2 (en) 2002-08-22
US8642745B2 (en) 2014-02-04
DE69830901T2 (de) 2006-05-24
EP0979281A2 (en) 2000-02-16
CA2288600A1 (en) 1998-11-12
DE69830901D1 (de) 2005-08-25
DK0979281T3 (da) 2005-11-21
WO1998050431A2 (en) 1998-11-12
AU7270998A (en) 1998-11-27
ATE299938T1 (de) 2005-08-15
JP2001523971A (ja) 2001-11-27
WO1998050431A3 (en) 1999-01-14
CA2288600C (en) 2010-06-01
US20140322756A1 (en) 2014-10-30
JP2009039122A (ja) 2009-02-26

Similar Documents

Publication Publication Date Title
IL132560A0 (en) A method for making multispecific antibodies having heteromultimeric and common components
MX9706493A (es) Metodo para producir polipeptidos heteromultimericos.
WO2001070984A3 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
WO1997037029B1 (en) MONOCLONAL ANTIBODIES SPECIFIC FOR THE PLATELET DERIVED GROWTH FACTOR β RECEPTOR AND METHODS OF USE THEREOF
AU3066489A (en) Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
AU1986588A (en) Growth hormone receptor
EP0267781A3 (en) Method for selecting hybridomas producing antibodies specific to the p-glycoprotein cell surface antigen and a cdna clone encoding the c-term
WO1995030750A8 (fr) Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
WO2000001815A3 (en) Neurotrophic factors
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
NL300419I1 (nl) Werkwijze voor het bereiden van heterologe bispecifieke antilichamen
WO1999062526A3 (en) Use of genetically engineered antibodies to cd38 to treat multiple myeloma
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
AU5117290A (en) Intercellular adhesion molecule - 2 and its binding ligands
EP0728215A4 (en) METHOD FOR BINDING MATERIAL TO THE -g (b) AMYLOID PEPTIDE
DE59914490D1 (de) Ein faktor viii-polypeptid mit faktor viii:c-aktivität
WO2000023565A3 (en) Novel neuropilin/growth factor binding and uses thereof
WO1997011968A3 (en) A gene associated with liver neoplastic disease
WO1996023884A3 (en) Human peroxisome proliferator activated receptors
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
AU5326198A (en) Synthetic biepitope compounds which can be used as standards in the biological assays of troponin I
WO2002068615A3 (en) Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives
JPS6468661A (en) Immunological method for determining isolated substance having hapten nature
CA2180957A1 (en) Cloning and recombinant production of crf receptor(s)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired